ElevateBio is based in Cambridge. It has raised $1.3B in total funding. Latest round: Series D.
ElevateBio funding overview
ElevateBio is based in Cambridge. ElevateBio has raised $1.3B in total disclosed funding. That places its disclosed total in over $1B. Its most recent disclosed round is a Series D announced in May 2023. The round record for ElevateBio runs through 2023; nothing later has been disclosed. Investors on record include AyurMaya Capital Management, Matrix Capital Management, Woodline, Lee Family Office, Novo Nordisk, The Invus Group and 12 others. 18 distinct backers are named across the disclosed rounds.
ElevateBio at a glance
Total raised
$1.3B
Latest round
Series D
Latest round date
May 2023
Headquarters
Cambridge
Notable investors
AyurMaya Capital Management, Matrix Capital Management, Woodline, Lee Family Office, Novo Nordisk, The Invus Group, Emerson Collective, SoftBank Vision Fund 2
Frequently asked about ElevateBio funding
How much has ElevateBio raised?
ElevateBio has raised $1.3B in total disclosed funding across the rounds on record.
Who has invested in ElevateBio?
AyurMaya Capital Management, Matrix Capital Management, Woodline, Lee Family Office, Novo Nordisk, The Invus Group are named among the investors backing ElevateBio.
What was the latest ElevateBio funding round?
The most recent disclosed round is a Series D, announced in May 2023.
Where is ElevateBio based?
ElevateBio is based in Cambridge.
When did ElevateBio last raise?
The last disclosed ElevateBio round closed in May 2023 at Series D.
ElevateBio totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Cambridge below to benchmark round size and investor mix.
